- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IV Uveal Melanoma
- Interventions
- Dacarbazine, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Selumetinib, Temozolomide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 32
- States / cities
- Aurora, Colorado • Miami Beach, Florida • Tampa, Florida + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 33
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hodgkin Lymphoma
- Interventions
- Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab, Dacarbazine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma
- Interventions
- Interferon-2A, Adriamycin, Bleomycin, Velban, Dacarbazine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
- Interventions
- Bleomycin, Brentuximab Vedotin, Dacarbazine, Doxorubicin, Nivolumab, Quality-of-Life Assessment, Vinblastine
- Drug · Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Recurrent Intraocular Melanoma
- Interventions
- recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Melanoma, Cutaneous Malignant
- Interventions
- IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel
- Biological · Drug
- Lead sponsor
- Immatics US, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
- Conditions
- Stage IV Melanoma
- Interventions
- Lenvatinib, Dacarbazine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 5
- States / cities
- Hagerstown, Maryland • Albany, New York • Greenville, South Carolina + 2 more
- Conditions
- Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma, Mixed Cellularity Classical Hodgkin Lymphoma, Nodular Sclerosis Classical Hodgkin Lymphoma
- Interventions
- Computed Tomography, Dacarbazine, Doxorubicin Hydrochloride, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pembrolizumab, Positron Emission Tomography, Vinblastine Sulfate
- Procedure · Drug · Radiation + 2 more
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 4
- States / cities
- Stanford, California • Atlanta, Georgia • Chicago, Illinois + 1 more
- Conditions
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- Interventions
- Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 1,875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 400
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 296 more
- Conditions
- Unresectable or Metastatic Melanoma
- Interventions
- BMS-936558, Dacarbazine, Carboplatin, Paclitaxel
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- Sarcoma
- Interventions
- Dacarbazine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Dacarbazine, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Vinblastine, Questionnaire
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 6
- States / cities
- Irvine, California • Palo Alto, California • Boston, Massachusetts + 3 more
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Dacarbazine, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pembrolizumab, Vinblastine
- Drug · Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Classic Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Echocardiography Test, Gemcitabine, Pembrolizumab, Physical Performance Testing, Positron Emission Tomography, Pulmonary Function Test
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Lymphoma
- Interventions
- Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Vincristine, Mechlorethamine, Etoposide, Prednisone, Cyclophosphamide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 16 Years and older
- Enrollment
- 854 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2016
- U.S. locations
- 517
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 329 more
- Conditions
- Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Uveal Melanoma AJCC v7
- Interventions
- Cabozantinib S-malate, Dacarbazine, Laboratory Biomarker Analysis, Temozolomide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 224
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Burbank, California + 141 more
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- Classic Hodgkin Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Dacarbazine, Doxorubicin, Echocardiography, Multigated Acquisition Scan, Pembrolizumab, Positron Emission Tomography, Vinblastine
- Procedure · Drug · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 4
- States / cities
- Stanford, California • Chicago, Illinois • Geneva, Illinois + 1 more
- Conditions
- Lymphoma
- Interventions
- Doxorubicin, Bleomycin, Vinblastine, PET, INRT, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
- Drug · Diagnostic Test · Radiation
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Stanford, California • Reading, Pennsylvania
- Conditions
- Solid Tumor, Thyroid Cancer
- Interventions
- Capecitabine (Xeloda), DTIC-Dome (Dacarbazine), Gleevec (Imatinib Mesylate)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Uveal Melanoma
- Interventions
- IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more
- Conditions
- Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
- Interventions
- Brentuximab Vedotin, Dacarbazine, Doxorubicin, Laboratory Biomarker Analysis, Nivolumab, Vinblastine
- Drug · Other · Biological
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 9
- States / cities
- Duarte, California • Rochester, Minnesota • Omaha, Nebraska + 6 more
- Conditions
- Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
- Interventions
- Bleomycin, Dacarbazine, Doxorubicin Hydrochloride, Rituximab, Vinblastine
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 17 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 4
- States / cities
- Miami, Florida • Chicago, Illinois • New York, New York + 1 more
- Conditions
- Malignant Melanoma
- Interventions
- ABI-007, Dacarbazine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 529 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 33 more